In early 2024, Melodiol Global Health (ASX: ME1), formerly known as Creso Pharma, faced scrutiny from the ASX, regarding corporate…
Recreational cannabis use has been a global topic for debate in the past few years but cannabinoids, a naturally occurring…
Over the past several months, medical cannabis company Melodiol Global Health’s (ASX: ME1) subsidiary Health House Australia has been gearing…
In Australia, about 43% of people aged between 16 and 85 had experienced a mental disorder at some point as…
After changing its name and identity, cannabis and psychedelics provider Melodiol (ASX: ME1) has decided to sell off two of…
Three CEOs within 18 months, a serious listing breach, and an ASX censure. It seems like the stars were not…